228 related articles for article (PubMed ID: 16750913)
41. Antisense strategies for oncogene inactivation.
Stein CA; Benimetskaya L; Mani S
Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
[TBL] [Abstract][Full Text] [Related]
42. [Effects of anti-gene and antisense therapeutics on human prostate cancer xenograft in nude mice].
Zhang Y; Ma Y; Lu HP; Zhou XF; Xie Y; Gao JH; Liang CS
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(29):2073-6. PubMed ID: 19080439
[TBL] [Abstract][Full Text] [Related]
43. The future of antisense oligonucleotides in the treatment of respiratory diseases.
Ulanova M; Schreiber AD; Befus AD
BioDrugs; 2006; 20(1):1-11. PubMed ID: 16573347
[TBL] [Abstract][Full Text] [Related]
44. State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers.
Fattal E; Bochot A
Int J Pharm; 2008 Dec; 364(2):237-48. PubMed ID: 18619528
[TBL] [Abstract][Full Text] [Related]
45. New molecular targets in advanced prostate cancer.
Dawson NA
Expert Rev Anticancer Ther; 2006 Jul; 6(7):993-1002. PubMed ID: 16831072
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3.
Li WC; Ye SL; Sun RX; Liu YK; Tang ZY; Kim Y; Karras JG; Zhang H
Clin Cancer Res; 2006 Dec; 12(23):7140-8. PubMed ID: 17145839
[TBL] [Abstract][Full Text] [Related]
47. Therapeutic potential of antisense nucleic acid molecules.
Opalinska JB; Gewirtz AM
Sci STKE; 2003 Oct; 2003(206):pe47. PubMed ID: 14583589
[TBL] [Abstract][Full Text] [Related]
48. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
49. Reduction of liver tumor necrosis factor-alpha expression by targeting delivery of antisense oligonucleotides into Kupffer cells protects rats from fulminant hepatitis.
Dong L; Zuo L; Xia S; Gao S; Zhang C; Chen J; Zhang J
J Gene Med; 2009 Mar; 11(3):229-39. PubMed ID: 19189285
[TBL] [Abstract][Full Text] [Related]
50. Antisense-mediated melanoma inhibitor of apoptosis protein downregulation sensitizes G361 melanoma cells to cisplatin.
Mousavi-Shafaei P; Ziaee AA; Azizi E; Zangemeister-Wittke U
Anticancer Drugs; 2006 Oct; 17(9):1031-9. PubMed ID: 17001176
[TBL] [Abstract][Full Text] [Related]
51. Individualized therapy of disseminated cancer using malignant melanoma as a model.
Hauschild A; Egberts F; Russo P; Kähler KC
Cancer Metastasis Rev; 2006 Jun; 25(2):253-6. PubMed ID: 16770537
[TBL] [Abstract][Full Text] [Related]
52. Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma.
Mateo-Lozano S; Gokhale PC; Soldatenkov VA; Dritschilo A; Tirado OM; Notario V
Clin Cancer Res; 2006 Nov; 12(22):6781-90. PubMed ID: 17121899
[TBL] [Abstract][Full Text] [Related]
53. Targeting miR-21 in glioma: a small RNA with big potential.
Moore LM; Zhang W
Expert Opin Ther Targets; 2010 Nov; 14(11):1247-57. PubMed ID: 20942748
[TBL] [Abstract][Full Text] [Related]
54. Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer.
Hamakawa H; Nakashiro K; Sumida T; Shintani S; Myers JN; Takes RP; Rinaldo A; Ferlito A
Head Neck; 2008 Jun; 30(6):800-9. PubMed ID: 18429007
[TBL] [Abstract][Full Text] [Related]
55. The disposition (ADME) of antisense oligonucleotides.
Dvorchik BH
Curr Opin Mol Ther; 2000 Jun; 2(3):253-7. PubMed ID: 11249618
[TBL] [Abstract][Full Text] [Related]
56. Intravesically administered antisense oligonucleotides targeting heat-shock protein-27 inhibit the growth of non-muscle-invasive bladder cancer.
Hadaschik BA; Jackson J; Fazli L; Zoubeidi A; Burt HM; Gleave ME; So AI
BJU Int; 2008 Aug; 102(5):610-6. PubMed ID: 18384625
[TBL] [Abstract][Full Text] [Related]
57. Antisense oligonucleotides as therapeutic agents.
Alama A; Barbieri F; Cagnoli M; Schettini G
Pharmacol Res; 1997 Sep; 36(3):171-8. PubMed ID: 9367660
[TBL] [Abstract][Full Text] [Related]
58. Antisense technology and prospects for therapy of viral infections and cancer.
Wagner RW; Flanagan WM
Mol Med Today; 1997 Jan; 3(1):31-8. PubMed ID: 9021740
[TBL] [Abstract][Full Text] [Related]
59. [Recent progress and prospect in oligonucleotide therapeutics].
Yoshioka K; Kuwahara H; Nishina K; Nagata T; Yokota T
Nihon Rinsho; 2015 Jun; 73(6):1057-65. PubMed ID: 26065142
[TBL] [Abstract][Full Text] [Related]
60. Antisense therapy in malignant diseases: status quo and quo vadis?
Tamm I
Clin Sci (Lond); 2006 Apr; 110(4):427-42. PubMed ID: 16526947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
